Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition

Last updated: September 30, 2020
Sponsor: 59th Medical Wing
Overall Status: Trial Not Available

Phase

3

Condition

Bowel Dysfunction

Gastroparesis

Heartburn (Pediatric)

Treatment

N/A

Clinical Study ID

NCT01052896
FWH20090188H
WS499026
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the effectiveness of gabapentin on symptom control in patients with defined functional dyspepsia refractory to conventional proton pump inhibitor therapy and to compare these effects to that of placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients to be included in this study are adults (age >18 years) with definedfunctional dyspepsia per the ROME III criteria with a negative EGD who are on protonpump inhibitor therapy yet still have a sense of inadequate symptom control.

Exclusion

Exclusion Criteria:

  • Patients excluded will be women of childbearing age who refuse to have a baselinepregnancy test and/or who refuse to prevent pregnancy during the trial period.Exclusion criteria will also include anyone with a history of adverse effect orallergy to gabapentin. Finally, any patient undergoing hemodialysis or with a historyof creatinine chronically greater than 1.5 will be excluded.

Study Design

Study Start date:
March 01, 2010
Estimated Completion Date:
August 28, 2012

Study Description

In this pilot study we hypothesize that the patients on gabapentin will have an increase in the adequacy of dyspepsia symptom control at two months as well as improvement in dyspepsia symptom index scores which are a surrogate of quality of life measures, when compared to placebo.

While functional dyspepsia is divided into four subtypes most studies have grouped all four as 'functional dyspepsia' and treated them as one. Proton pump inhibition may benefit those with epigastric pain or burning but typically not those with post-prandial fullness or early satiety. (Tack et al). Those patients with symptoms refractory to proton pump inhibition might benefit from a medication that modifies visceral hypersensitivity such as gabapentin. It is possible that by modifying their pain syndrome we can decrease the need for follow-up appointments and improve patient quality of life.

Connect with a study center

  • San Antonio Military Medical Center - North

    San Antonio, Texas 78236
    United States

    Site Not Available

  • San Antonio Military Medical Center - South

    San Antonio, Texas 78236
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.